Product Information
BUSPIRONE HCL 7.5 MG TABLET is a generic product labeled by Advagen Pharma Ltd., priced at $0.1003 per EA under NDC 72888006305. Its NADAC has been published 162 times since Aug 30, 2023.
FDA first approved this application on Apr 5, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
7.5 mg/1
Manufacturer
Advagen Pharma Ltd.NDC
72888006305
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BUSPIRONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA075521FDA Approved
4/5/2002
TE Code
AB
On Market Since
3/16/2021
Price Statistics
The NADAC for BUSPIRONE HCL 7.5 MG TABLET has been published 162 times since Aug 30, 2023, and over the history we have for it it has declined 38.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1003 per EA |
|---|---|
| All-time high | $0.1623 (Sep 13, 2023) |
| All-time low | $0.0797 (Nov 20, 2024) |
| 52-week high | $0.1212 |
| 52-week low | $0.1003 |
| Median price | $0.1187 |
| Average price | $0.1194 |
| Largest weekly change | -42.2% (Nov 20, 2024) |
| Weeks tracked | 162 |
| Tracking since | Aug 30, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Advagen Pharma Ltd. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
buspirone hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUSPIRONE HCL 7.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUSPIRONE HCL 7.5 MG TABLET, manufactured by Advagen Pharma Ltd., is $0.1003 per EA (NDC 72888006305), effective Sep 30, 2026.
How has the price of BUSPIRONE HCL 7.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUSPIRONE HCL 7.5 MG TABLET has declined 38.2%. It has been tracked across 162 weekly CMS publications since Aug 30, 2023.
What are the highest and lowest recorded NADAC prices for BUSPIRONE HCL 7.5 MG TABLET?
Since Aug 30, 2023, the NADAC for BUSPIRONE HCL 7.5 MG TABLET has ranged from a low of $0.0797 (Nov 20, 2024) to a high of $0.1623 (Sep 13, 2023), with a median of $0.1187 per EA.
Are there cheaper alternatives to BUSPIRONE HCL 7.5 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BUSPIRONE HCL 7.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures BUSPIRONE HCL 7.5 MG TABLET?
BUSPIRONE HCL 7.5 MG TABLET (NDC 72888006305) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.